Azitra, Inc. (AZTR)
| Market Cap | 3.79M -17.2% |
| Revenue (ttm) | n/a |
| Net Income | -10.96M |
| EPS | -2.25 |
| Shares Out | 16.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 282,736 |
| Open | 0.2370 |
| Previous Close | 0.2377 |
| Day's Range | 0.2273 - 0.2399 |
| 52-Week Range | 0.1000 - 2.3980 |
| Beta | -1.39 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+1,607.21%) |
| Earnings Date | May 22, 2026 |
About AZTR
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for AZTR stock is "Strong Buy" and the 12-month stock price target is $4.0.
News
Azitra granted new U.S. patent protecting ATR-12 program
Azitra (AZTR) announced the issuance of a new U.S. patent protecting ATR-12, the company’s lead product candidate. Azitra is advancing ATR-12 in a Phase 1b clinical trial as a treatment…
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein ATR-12 is currently the subject of a Phase 1b trial for the treatmen...
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Preclinical data demonstrate ATR-01 delivers functional filaggrin, restoring skin barrier integrity and supporting advancement toward first-in-human studies BRANFORD, Conn., April 28, 2026 /PRNewswire...
Why Is Azitra Inc Stock (AZTR) Up Today?
Azitra Inc stock climbed on Friday after the company revealed details of a private placement.
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Initial funding of approximately $10.5MM in convertible preferred stock and up to an additional $20.9MM upon cash exercise of warrants Financing marks launch of Azitra new innovative protein and pepti...
Azitra Inc trading halted, news pending
12:23 EDT Azitra (AZTR) Inc trading halted, news pending
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for...
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermat...
Azitra adds MD Anderson Cancer Center as site for Phase 1/2 skin rash trial
Azitra (AZTR) added The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04. ATR-04 is a first-in-class, topically applied…
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestones BRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azit...
Azitra, Inc. to Present at BIO Investment & Growth Summit
BRANFORD, Conn., Feb. 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, toda...
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
BRANFORD, Conn., Jan. 7, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermato...
Azitra says NYSE American approves compliance plan
Azitra (AZTR) announced it received a notice from the staff of NYSE American approving Azitra’s plan to come into compliance with the Exchange’s continued listing standards under Section 1003(a)(ii) o...
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
BRANFORD, Conn. , Dec. 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra files to sell 38.9M shares of common stock for holders
16:12 EST Azitra (AZTR) files to sell 38.9M shares of common stock for holders
Azitra prices 4.69M share private placement at 32c per share
Maxim Group LLC is acting as the sole placement agent in connection with the Offering.
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
BRANFORD, Conn. , Nov. 24, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision derma...
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
BRANFORD, Conn. , Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision derma...
Azitra says report of $44M registered direct offering is false
Azitra (AZTR) announced that it has come to the company’s attention that a report has been circulated claiming that the company priced a $44M registered direct offering. The company said,…
Azitra, Inc. Addresses False Report Regarding Sale of Securities
BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, toda...
Azitra to present preclinical progress for its ATR-01 program
Azitra (AZTR) announced that Cofounder and COO, Travis Whitfill, will present positive preclinical progress for its ATR-01 program, targeting the treatment of ichthyosis vulgaris, a disease caused by ...
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris Preclinical data show production of active, functional filaggrin delivered thro...